Anavex Life Sciences Files Definitive Proxy Statement
Ticker: AVXL · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1314052
| Field | Detail |
|---|---|
| Company | Anavex Life Sciences Corp. (AVXL) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Anavex proxy filed - shareholders vote on directors & company proposals.
AI Summary
Anavex Life Sciences Corp. filed its definitive proxy statement (DEF 14A) on April 25, 2025, for its annual meeting. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of the independent auditor.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership and proposals, enabling informed voting decisions that can impact the company's strategic direction and governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently introduce new business risks.
Key Players & Entities
- ANAVEX LIFE SCIENCES CORP. (company) — Registrant
- 0001731122-25-000607 (filing_id) — Accession Number
- 20250425 (date) — Filing Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing detailed information about matters to be voted upon.
When was this DEF 14A filed by Anavex Life Sciences Corp.?
This DEF 14A was filed on April 25, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on September 30 (0930).
What is the Standard Industrial Classification (SIC) code for Anavex Life Sciences Corp.?
The SIC code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the business address of Anavex Life Sciences Corp.?
The business address is 630 5TH AVENUE, 20TH FLOOR, NEW YORK, NY 10111.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding ANAVEX LIFE SCIENCES CORP. (AVXL).